Previous 10 | Next 10 |
home / stock / ivevf / ivevf news
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the m...
Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure. ...
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic d...
2024-03-28 11:27:08 ET Inventiva S.A. (IVA) Q4 2023 Results Conference Call March 28, 2024 08:00 AM ET Company Participants Frederic Cren - CEO Jean Volatier - CFO Conference Call Participants Seamus Fernandez - Guggenheim Securities Rami Katkhuda - L...
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysf...
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million 1 , and long-term deposit at €9.0 million 2 as of December 31, 2023, comp...
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatoh...
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid meta...
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of me...
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. Screening of patients is resuming in sites operating under central IRB in the US. Other sites and count...
News, Short Squeeze, Breakout and More Instantly...
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1 This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrho...
Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term. Cash runway extended...
Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3. Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a pat...